Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002-2011

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1881-1886

  Kadivar, Maryam ^a   Mafi, Negar ^a   Joulaee, Azadeh ^b   Shamshiri, Ahmad ^a   Hosseini, Niloufar ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Clinicopathological characteristics; Immunohistochemistry; Iran; Molecular subtypes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; CLASSIFICATION; FEMALE; HUMAN; IRAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IRAN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84872677232     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1881     Document Type: Article

References (35)

1. Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study. BMC Cancer, 10, 223.
2. American Cancer Society (2011). Global Cancer Facts & Figures 2nd Edition. Atlanta.
3. Anders C, Carey LA (2008). Understanding and treating triple-negative breast cancer. Oncology, 22, 1233-9.
4. Ben Abdelkrim S, Trabelsi A, Missaoui N, et al (2010). Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: A study of 194 patients. Pathol Res Pract, 206, 772-5.
5. Bhargava R, Striebel J, Beriwal S, et al (2009). Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J clin Exp Pathol, 2, 444-55.
6. Blackman DJ, Masi CM (2006). Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes?. J Clin Oncol, 24, 2170-8
7. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23, 7350-60.
8. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA, 295, 2492-502.
9. Crabb SJ, Cheang MC, Leung S, et al (2008). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer, 8, 249-56.
10. de Azambuja E, Cardoso F, de Castro G Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13.
11. Del Casar JM, Martín A, García C, et al (2008). Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol, 141, 147-52.
12. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M (1996). Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res, 2, 147-54.
13. Harirchi I, Kolahdoozan S, Karbakhsh M, et al (2011). Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol, 22, 93-7.
14. Huber KE, Carey LA, Wazer DE (2009). Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol, 19, 204-10.
15. Huo D, Ikpatt F, Khramtsov A, et al (2009). Population differences in breast cancer: survey indigenous african women reveals over-representation of triple-negative breast cancer. J Clin Oncol, 27, 4515-21.
16. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res, 143, 109-18.
17. Iranian Annual of National Cancer Registration Report (2008-2009). Islamic Republic of Iran, Ministry of health and medical education, Center for disease control & prevention, non-communicable diseases unit, cancer office.
18. Keshgegian AA, Cnaan A (1995). Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol, 104, 42-9.
19. Kim MJ, Ro JY, Ahn SH, et al (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-over expressing phenotypes. Hum Pathol, 37, 1217-26.
20. Ma CX, Sanchez CG, Ellis MJ (2009). Predicting endocrine therapy responsiveness in breast cancer. Oncology, 23, 133-42.
21. Miron L, Marinca A, Marinca M, Miron I (2008). Triple-negative breast cancer-towards a new entity. Rev Med Chir Soc Med Nat Iasi, 112, 51-8.
22. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91.
23. Munoz M, Fernández-Acenero MJ, Martín S, Schneider J (2009). Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet, 280, 43-8.
24. Nguyen PL, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol, 26, 2373-8.
25. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF (2006). Molecular classification of breast cancer: limitations and potential. Oncologist, 11, 868-77.
26. Salhia B, Tapia C, Ishak EA, et al (2011). Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Women's Health, 11, 44.
27. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
28. Sørlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
29. Spitale A, Mazzola P, Soldini D, Mazzucchelli L Bordoni A (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland. Ann Oncol, 20, 628-35.
30. Tian XS, Cong MH, Zhou WH, et al (2008). Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie, 31, 610-4.
31. Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer, 97, 1321-3.
32. Wiechmann L, Sampson M, Stempel M, et al (2009). Presenting features of breast cancer differ by molecular subtype (2009). Ann Surg Oncol, 16, 2705-10.
33. Yang XR, Sherman ME, Rimm DL, et al (2007). Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev, 16, 439-43.
34. Zaha DC, Lazar E, Lazureanu C (2010). Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol, 51, 85-9.
35. Zhao J, Liu H, Wang M, et al (2009). Characteristics and prognosis for molecular breast cancer subtypes in chinese women. J Surg Oncol, 100, 89-94.